TY - JOUR
T1 - Activation of the A10 mesolimbic system by the σ-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic
AU - Ceci, Angelo
AU - Smith, Melinda
AU - French, Edward D.
N1 - Funding Information:
This work was supported by USPHS Grant DA 03876 Dr (ec~ is a fellow of the program of advanced trmmng established by EEC and ReDone Lobardla on leave from the Mano Negn lnstLtute of Pharmacological Research Milan Ital,~ Also, we are grateful to Dr Robert Ferns and the Burroughs Wellcome Company for providing a generous supply of rlmcazole
PY - 1988/9/1
Y1 - 1988/9/1
N2 - This study evaluated with electrophysiological and behavioral techniques the ability of rimcazole, a novel putative antipsychotic and selective σ-receptor ligand, to antagonize the stimulation of the mesocorticolimbic dopamine system by the σ-agonist, (+)SKF 10,047. Rimcazole effectively blocked the (+)SKF 10,047-induced excitation of ventral tegmental dopamine neurons while having no effect on either spontaneous activity or apomorphine-elicited slowing of A10 firing. Rimcazole also antagonized the behavioral hyperactivity produced by (+)SKF 10,047, but not by d-amphetamine which is also mediated through the same mesolimbic dopamine pathway. These data provide further evidence that rimcazole's novel pharmacologic profile may involve a blockade of σ-receptors on mesocorticolimbic dopamine neurons.
AB - This study evaluated with electrophysiological and behavioral techniques the ability of rimcazole, a novel putative antipsychotic and selective σ-receptor ligand, to antagonize the stimulation of the mesocorticolimbic dopamine system by the σ-agonist, (+)SKF 10,047. Rimcazole effectively blocked the (+)SKF 10,047-induced excitation of ventral tegmental dopamine neurons while having no effect on either spontaneous activity or apomorphine-elicited slowing of A10 firing. Rimcazole also antagonized the behavioral hyperactivity produced by (+)SKF 10,047, but not by d-amphetamine which is also mediated through the same mesolimbic dopamine pathway. These data provide further evidence that rimcazole's novel pharmacologic profile may involve a blockade of σ-receptors on mesocorticolimbic dopamine neurons.
KW - A10 dopamine neurons
KW - Locomotor behavior
KW - Rimcazole
KW - SKF 10,047 (N-allylnormetazocine)
KW - σ Receptors
UR - http://www.scopus.com/inward/record.url?scp=0023820905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023820905&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(88)90362-7
DO - 10.1016/0014-2999(88)90362-7
M3 - Article
C2 - 2903063
AN - SCOPUS:0023820905
SN - 0014-2999
VL - 154
SP - 53
EP - 57
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1
ER -